| Literature DB >> 29263081 |
Jennifer L Hu1, Michael E Todhunter2, Mark A LaBarge2, Zev J Gartner3,4,5.
Abstract
The biology of aging is challenging to study, particularly in humans. As a result, model organisms are used to approximate the physiological context of aging in humans. However, the best model organisms remain expensive and time-consuming to use. More importantly, they may not reflect directly on the process of aging in people. Human cell culture provides an alternative, but many functional signs of aging occur at the level of tissues rather than cells and are therefore not readily apparent in traditional cell culture models. Organoids have the potential to effectively balance between the strengths and weaknesses of traditional models of aging. They have sufficient complexity to capture relevant signs of aging at the molecular, cellular, and tissue levels, while presenting an experimentally tractable alternative to animal studies. Organoid systems have been developed to model many human tissues and diseases. Here we provide a perspective on the potential for organoids to serve as models for aging and describe how current organoid techniques could be applied to aging research.Entities:
Mesh:
Year: 2017 PMID: 29263081 PMCID: PMC5748992 DOI: 10.1083/jcb.201709054
Source DB: PubMed Journal: J Cell Biol ISSN: 0021-9525 Impact factor: 10.539
Figure 1.Types of organoids. (A) Tissue fragments and explants are generated from native tissue with little disruption to cell and ECM organization and no intermediate period in 2D culture. This limits total sample size and manipulability but is unmatched in mimicking the original tissue. (B) Reconstituted organoids are assembled in vitro from cultured or sorted cells. This permits cell expansion and modular assembly of components. However, some subpopulations or phenotypes, such as senescent and hormone-responsive cells, may be lost during culture. (C) Stem cell–derived organoids are differentiated from multipotent adult tissue stem cells or PSCs under the appropriate differentiation and maintenance conditions. PSCs specifically can generate rare tissue and cell types, but have limited maturity and lose the hallmarks of aging.
Examples of rodent and human tissues cultured as organoids
| Tissue | Type | Examples | ||
|---|---|---|---|---|
| Tissue fragments | Reconstituted | Stem cell derived | ||
| Central nervous system: brain, retina | Human, rat | Rat | hiPSC, hESC | |
| Gastrointestinal: esophagus, stomach, small intestine, colon | Human, mouse | Human, mouse, hPSC, mESC | ||
| Pancreas | Human, mouse | Human, mouse, hiPSC | ||
| Liver | Human, mouse | Human | Human, mouse, hiPSC | |
| Kidney | Mouse | Human, mouse | hiPSC, hESC | |
| Lung | Human, mouse | Human, mouse | hiPSC, mouse | |
| Muscle: skeletal, cardiac | Human, rat, mouse | hiPSC | ||
| Skin | Human | Human | ||
| Cartilage | Human | Human | hMSC | |
| Artery | Rat | Human, mouse | ||
| Mammary gland | Human, mouse | Human | Human | |
| Prostate | Human | Human, rat | Human, mouse | |
| Ovary, endometrium | Human | Human | ||
| Thyroid | Human | mESC | ||
Organoid culture has now been extended to a variety of tissues, including many from adult human primary tissue or cells. h, human; m, mouse; MSC, mesenchymal stem cell.
Summary of current limitations and areas for development in organoid culture for aging
| Goals | Approaches | Challenges |
|---|---|---|
| Increase developmental maturity of pluripotent stem cell–derived organoids | Long-term culture ( | Stem cells are highly sensitive to culture conditions, impeding robust protocols |
| In vivo maturation ( | ||
| Mechanical or electrical conditioning of muscle and cartilage ( | ||
| Improved culture conditions and differentiation protocols | ||
| Acceleration by small molecules ( | ||
| Source culturable, age-varied human cells | Surgical discards from elective surgery, transplant trimmings, and tissue peripheral to tumors | Hard to source certain tissues, especially healthy, culturable adult cells |
| Cells adapt to culture and are not infinitely renewable | ||
| Nontumor peripheral tissue may differ from healthy tissue | ||
| In vitro aging to model the effects of specific age-related lesions and provide a source of artificially aged cells | Induced senescence by DNA damage or environmental stress ( | Controversial which treatments best phenocopy aging |
| Long-term culture ( | ||
| Progeria mutations ( | ||
| Direct reprogramming of aged cells ( | ||
| Mimic the effects of the aged ECM in vitro | ECM from aged donors ( | Controversial which treatments best phenocopy aging |
| Glycation crosslinking ( | ECM extraction from tissues can alter its mechanical properties, microstructure, and composition | |
| Enzymatic crosslinking ( | ||
| Develop aging-relevant experimental readouts | Epigenetic clock ( | Unclear which signs of aging are most important |
| Mutational analysis ( | Require signs of aging that change appreciably across the span of an experiment | |
| Protein/DNA oxidation | ||
| Protein aggregation | ||
| Tissue-specific functional assays | ||
| Long-term maintenance of organoids in a stable, growth-arrested state | Improved culture media | Relatively few published maintenance conditions |
| Improved ECM and bioreactors | Vetting culture conditions is lengthy | |
| Complete modeling of whole organs and physiological systems | Co-culture with immune cells, stromal cells, and microbiome bacteria ( | Few good techniques for sophisticated organoid construction |
| Increase throughput and reproducibility | Vascularization ( | Powerful techniques are often cumbersome and low-throughput |
| Innervation ( | ||
| In vivo implantation ( | ||
| Microfluidic access to apical/basal fluid reservoirs and fluid transport between organ systems ( | ||
| Organ-specific ECM ( | ||
| Defined artificial ECMs may decrease lot-to-lot variability ( | ||
| Growth factor distribution within ECM gels for spatial control over growth and differentiation ( | ||
| Cell patterning for control over initial organoid shape and composition ( | ||
| 3D-printed gels amenable to perfusion with control over large-scale tissue structure ( | ||
| Morphological screening and sorting to enrich for correctly formed organoids ( |